These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 2857269)
1. New tactics for type 2 diabetes: regimens based on intermediate-acting insulin taken at bedtime. Riddle MC Lancet; 1985 Jan; 1(8422):192-5. PubMed ID: 2857269 [TBL] [Abstract][Full Text] [Related]
2. Optimized postprandial glucose control is associated with improved cardiac/vascular function - comparison of three insulin regimens in well-controlled type 2 diabetes. Bibra Hv; Siegmund T; Ceriello A; Volozhyna M; Schumm-Draeger PM Horm Metab Res; 2009 Feb; 41(2):109-15. PubMed ID: 19214920 [TBL] [Abstract][Full Text] [Related]
3. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810 [TBL] [Abstract][Full Text] [Related]
4. Intermediate acting insulin given at bedtime: effect on blood glucose concentrations before and after breakfast. Francis AJ; Home PD; Hanning I; Alberti KG; Tunbridge WM Br Med J (Clin Res Ed); 1983 Apr; 286(6372):1173-6. PubMed ID: 6404377 [TBL] [Abstract][Full Text] [Related]
5. Reducing hypoglycaemia with insulin analogues. Heller S Int J Obes Relat Metab Disord; 2002 Sep; 26 Suppl 3():S31-6. PubMed ID: 12174321 [TBL] [Abstract][Full Text] [Related]
6. Is daytime insulin more physiologic and less atherogenic than bedtime insulin? Kanat M Med Hypotheses; 2007; 68(6):1228-32. PubMed ID: 17145138 [TBL] [Abstract][Full Text] [Related]
7. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. Plosker GL; Figgitt DP Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124 [TBL] [Abstract][Full Text] [Related]
8. Effect of conventional and intensified insulin therapy on free-insulin profiles and glycemic control in NIDDM. Lindström TH; Arnqvist HJ; von Schenck HH Diabetes Care; 1992 Jan; 15(1):27-34. PubMed ID: 1737539 [TBL] [Abstract][Full Text] [Related]
9. Mid- and high-ratio premix insulin analogues: potential treatment options for patients with type 2 diabetes in need of greater postprandial blood glucose control. Christiansen JS; Liebl A; Davidson JA; Ligthelm RJ; Halimi S Diabetes Obes Metab; 2010 Feb; 12(2):105-14. PubMed ID: 19895637 [TBL] [Abstract][Full Text] [Related]
11. Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes. Linn T; Fischer B; Soydan N; Eckhard M; Ehl J; Kunz C; Bretzel RG J Clin Endocrinol Metab; 2008 Oct; 93(10):3839-46. PubMed ID: 18611975 [TBL] [Abstract][Full Text] [Related]
12. Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials. Russell-Jones D; Gall MA; Niemeyer M; Diamant M; Del Prato S Nutr Metab Cardiovasc Dis; 2015 Oct; 25(10):898-905. PubMed ID: 26232910 [TBL] [Abstract][Full Text] [Related]
13. Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose. Clemmons DR; Moses AC; Sommer A; Jacobson W; Rogol AD; Sleevi MR; Allan G Growth Horm IGF Res; 2005 Aug; 15(4):265-74. PubMed ID: 16005252 [TBL] [Abstract][Full Text] [Related]
14. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Juhl CB; Hollingdal M; Sturis J; Jakobsen G; Agersø H; Veldhuis J; Pørksen N; Schmitz O Diabetes; 2002 Feb; 51(2):424-9. PubMed ID: 11812750 [TBL] [Abstract][Full Text] [Related]
15. Improvement in bedtime plasma glucose level serves as a predictor of long-term blood glucose control in patients with Type 2 diabetes: a study with monotherapy of 50/50 premixed insulin analogue three times daily injection. Tanaka M; Ishii H J Diabetes Complications; 2011; 25(2):83-9. PubMed ID: 20573523 [TBL] [Abstract][Full Text] [Related]
16. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Rosenstock J; Park G; Zimmerman J; Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511 [TBL] [Abstract][Full Text] [Related]
17. Glycaemia control in diabetes mellitus. Towards the normal profile? Zimmerman BR Drugs; 1994 Apr; 47(4):611-21. PubMed ID: 7516860 [TBL] [Abstract][Full Text] [Related]
18. Insulin therapy in type 2 diabetes: what is the evidence? van Avendonk MJ; Rutten GE Diabetes Obes Metab; 2009 May; 11(5):415-32. PubMed ID: 19175375 [TBL] [Abstract][Full Text] [Related]
19. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study. Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500 [TBL] [Abstract][Full Text] [Related]
20. Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin. Abbasi F; Carantoni M; Chen YD; Reaven GM Diabetes Care; 1998 Aug; 21(8):1301-5. PubMed ID: 9702437 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]